CStone Pharma disclosed on 29 June 2026 that its issued share capital remained unchanged at 1.60 billion ordinary shares as of the close on 26 June 2026, with no treasury shares outstanding.

Between 15 and 26 June 2026 the company repurchased a total of 4.60 million shares on the Stock Exchange of Hong Kong for cancellation, equal to approximately 0.29% of its existing share base. The volume-weighted average repurchase price was roughly HKD 4.65 per share, bringing the aggregate consideration to about HKD 21.35 million.

The latest daily transaction, executed on 26 June 2026, involved 421,000 shares bought at prices ranging from HKD 4.37 to HKD 4.41, for a total outlay of HKD 1.85 million.

Under the general mandate approved on 23 June 2026, CStone Pharma may repurchase up to 159.74 million shares. As of 26 June 2026, 1.26 million shares—around 0.08% of the company’s issued share capital on the mandate date—have been acquired under this authority.

All 4.60 million repurchased shares are pending cancellation; until at least 26 July 2026 the company is restricted from issuing new shares or disposing of treasury shares under Hong Kong listing rules.